Risperidone half-life in a patient taking paroxetine: A case report

Pharmacopsychiatry

Volumn 38, Issue 5, 2005, Pages 223-225

  Barnhill, J ^a   Susce, M T ^a   Diaz, F J ^b   De Leon, Jose ^a,c  

^a Eastern State Hospital   (United States)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^c EASTERN STATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; PAROXETINE; RISPERIDONE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; GENOTYPE; HUMAN; LABORATORY TEST; MALE; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; HALF-LIFE; HUMANS; MALE; METABOLIC DETOXICATION, DRUG; PAROXETINE;

EID: 26244457406     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-873159     Document Type: Article

References (18)

1. Agid O, Lerer B. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology (letter). J Clin Psychiatry 1999; 60: 55-56
2. Alfaro CL, Lam YW, Simpson J et al. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 1999; 19: 155-163
3. Balant-Gorgia AE, Gex-Fabry M, Genet C et al. Therapeutic drug monitoring of risperidone using a new rapid HPLC method: reappraisal of interindividual variability factors. Ther Drug Monitior 1999; 21: 105-115
4. Baumann P, Hiemke C, Uhlrich S et al. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-256
5. Berecz R, LLerena A, de la Rubia A et al. Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry 2002; 35: 231-234
6. Bork J, Rogers T, Wedlund P et al. A pilot study of risperidone metabolism: The role of cytochrome P450 2D6 and 3A. J Clin Psychiatry 1999; 60: 469-476
7. Chou WH, Yan FX, Robbins-Weilert DK et al. Comparison of two CYP2D6 genotyping methods and assessments of genotype-phenotype relationships. Clin Chem 2003; 49: 542-551
8. de Leon J, Susce MT, Pan RM et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15-27
9. Ereshefsky L. Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 1996; 57 (Suppl 11): 12-25
10. Guzey C, Aamo T, Spigset O. Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer (letter). J Clin Psychiatry 2000; 61: 600-601
11. Huang M, Van Peer A, Woestenborghs R et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993; 54: 257-268
12. Kohnke MD, Griese EU, Stosser D et al. Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 2002; 35: 116-118
13. Martin K, Begaud B, Verdoux H et al. Patterns of risperidone prescription: a utilization study in south-west France. Acta Psychiatr Scand 2004; 109: 202-206
14. Megens AAHP, Awoteurs FHL, Schtte A et al. Survey on pharmacodynamics of the new antipsychotic risperidone. Psychopharmacol 1994; 114: 9-23
15. O'Connor M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression (letter). J Clin Psychopharmacol 1998; 18: 89-91
16. Spina E, Avenoso A, Facciola G et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 2001; 23: 223-227
17. Wang JS, Ruan Y, Taylor RM et al. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by p-glycoprotein. Int J Neuropsychopharmacology 2004; 7: 415-419
18. Wright JG, Boddy AV. All half-lives are wrong, but some half-lives are useful. Clin Pharmacokinet 2001; 40: 237-244